Prime Medicine (PRME) Shares Outstanding (2021 - 2026)

Prime Medicine (PRME) has 6 years of Shares Outstanding (Entity) data on file, last reported at $180.6 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 37.71% year-over-year to $180.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $180.6 million (up 37.71% YoY) and the FY2025 annual result came in at $148.8 million, up 13.42% from the prior year.
• Shares Outstanding (Entity) advanced to $180.6 million in Q1 2026, from $148.8 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $180.6 million in Q1 2026 to a low of $19.1 million in Q1 2022.
• A 5-year average of $103.7 million and a median of $120.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) soared 410.37% — and 2025, when it advanced 9.28%.
• Tracing PRME's Shares Outstanding (Entity) over 5 years: stood at $33.9 million in 2022, then soared by 187.32% to $97.4 million in 2023, then surged by 34.69% to $131.2 million in 2024, then increased by 13.42% to $148.8 million in 2025, then advanced by 21.42% to $180.6 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $180.6 million (Q1 2026), $148.8 million (Q4 2025), and $180.3 million (Q3 2025), per Business Quant data.